8 obese subjects,” International Journal of Obesity, vol. 27, no. 5, pp. 566–573, 2003. [42] S. Konstantinides, K. Scha¨fer, S. Koschnick, and D. J. Loskutoﬀ, “Leptin-dependent platelet aggregation and arte- rial thrombosis suggests a mechanism for atherothrombotic disease in obesity,” Journal of Clinical Investigation, vol. 108, no. 10, pp. 1533–1540, 2001. [43] S. Konstantinides, K. Scha¨fer, and D. J. Loskutoﬀ, “The prothrombotic eﬀects of leptin: possible implications for the risk of cardiovascular disease in obesity,” Annals of the New York Academy of Sciences, vol. 947, pp. 134–142, 2001. [44] S. Loﬀreda, S. Q. Yang, H. Z. Lin et al., “Leptin regulates proinﬂammatory immune responses,” FASEB Journal, vol. 12, no. 1, pp. 57–65, 1998. [45] F. Parhami, Y. Tintut, A. Ballard, A. M. Fogelman, and L. L. Demer, “Leptin enhances the calciﬁcation of vascular cells artery wall as a target of leptin,” Circulation Research, vol. 88, no. 9, pp. 954–960, 2001. [46] M. Laimer, C. F. Ebenbichler, S. Kaser et al., “Markers of chronic inﬂammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention,” Interna- tional Journal of Obesity, vol. 26, no. 5, pp. 659–662, 2002. [47] M. Maachi, L. Pie´roni, E. Bruckert et al., “Systemic low-grade inﬂammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women,” International Journal of Obesity, vol. 28, no. 8, pp. 993–997, 2004. [48] L. U. Monzillo, O. Hamdy, E. S. Horton et al., “Eﬀect of lifestyle modiﬁcation on adipokine levels in obese subjects with insulin resistance,” Obesity Research, vol. 11, no. 9, pp. 1048–1054, 2003. [49] D. K. Papafragkaki and G. Tolis, “Obesity and renal disease: a possible role of leptin,” Hormones, vol. 4, no. 2, pp. 90–95, 2005. [50] J. R. Henegar, S. A. Bigler, L. K. Henegar, S. C. Tyagi, and J. E. Hall, “Functional and structural changes in the kidney in the early stages of obesity,” Journal of the American Society of Nephrology, vol. 12, no. 6, pp. 1211–1217, 2001. [51] N. Kambham, G. S. Markowitz, A. M. Valeri, J. Lin, and V. D. D’Agati, “Obesity-related glomerulopathy: an emerging epidemic,” Kidney International, vol. 59, no. 4, pp. 1498– 1509, 2001. [52] P. Stenvinkel, “Leptin and its clinical implications in chronic renal failure,” Mineral and Electrolyte Metabolism, vol. 25, no. 4-6, pp. 298–302, 1999. [53] R. D. Adelman, “Obesity and renal disease,” Current Opinion in Nephrology and Hypertension, vol. 11, no. 3, pp. 331–335, 2002. [54] M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa, “Ghrelin is a growth-hormone-releasing acylated peptide from stomach,” Nature, vol. 402, no. 6762, pp. 656–660, 1999. [55] K. Takaya, H. Ariyasu, N. Kanamoto et al., “Ghrelin strongly stimulates growth hormone (GH) release in humans,” Jour- nal of Clinical Endocrinology and Metabolism, vol. 85, no. 12, pp. 4908–4911, 2000. [56] M. Iantorno, H. Chen, J. A. Kim et al., “Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells,” American Journal of Physiology, vol. 292, no. 3, pp. E756–E764, 2007. [57] M. Tesauro, M. Iantorno, F. Schinzari, and C. Cardillo, “Vascular eﬀects of insulin and their relation to endothelial Cardiology Research and Practice dysfunction, insulin resistance and hypertension,” Current Hypertension Reviews, vol. 5, no. 4, pp. 251–261, 2009. [58] M. Tesauro, F. Schinzari, M. Iantorno et al., “Ghrelin improves endothelial function in patients with metabolic syndrome,” Circulation, vol. 112, no. 19, pp. 2986–2992, 2005. [59] P. Cano, D. P. Cardinali, M. J. R´ıos-Lugo, M. P. Ferna´ndez- Mateos, C. F. Reyes Toso, and A. I. Esquiﬁno, “Eﬀect of a high-fat diet on 24-hour pattern of circulating adipocy- tokines in rats,” Obesity, vol. 17, no. 10, pp. 1866–1871, 2009. [60] A. H. Berg, T. P. Combs, X. Du, M. Brownlee, and P. E. Scherer, “The adipocyte-secreted protein Acrp30 enhances hepatic insulin action,” Nature Medicine, vol. 7, no. 8, pp. 947–953, 2001. [61] J. Fruebis, T. S. Tsao, S. Javorschi et al., “Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 4, pp. 2005–2010, 2001. [62] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance,” Science, vol. 259, no. 5091, pp. 87–91, 1993. [63] J. R. Sowers, “Endocrine functions of adipose tissue: focus on adiponectin,” Clinical Cornerstone, vol. 9, no. 1, pp. 32–38, 2008. [64] G. H. Goossens, E. E. Blaak, and M. A. Van Baak, “Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disor- ders,” Obesity Reviews, vol. 4, no. 1, pp. 43–55, 2003. [65] K. L. Comstock, K. A. Krown, M. T. Page et al., “LPS-induced TNF-α release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response,” Journal of Molecular and Cellular Cardiology, vol. 30, no. 12, pp. 2761–2775, 1998. [66] D. L. Mann, “Stress-activated cytokines and the heart: from adaptation to maladaptation,” Annual Review of Physiology, vol. 65, pp. 81–101, 2003. [67] G. Torre-Amione, S. Kapadia, J. Lee et al., “Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart,” Circulation, vol. 93, no. 4, pp. 704–711, 1996. [68] T. Yokoyama, L. Vaca, R. D. Rossen, W. Durante, P. Hazarika, and D. L. Mann, “Cellular basis for the negative inotropic eﬀects of tumor necrosis factor-α in the adult mammalian heart,” Journal of Clinical Investigation, vol. 92, no. 5, pp. 2303–2312, 1993. [69] H. H. Sigusch, M. H. Lehmann, U. Schnittler, D. Reinhardt, and H. R. Figulla, “Tumour necrosis factor-α expression in idiopathic dilated cardiomyopathy: correlation to myocardial inﬂammatory activity,” Cytokine, vol. 12, no. 8, pp. 1261– 1266, 2000. [70] S. Kapadia, J. Lee, G. Torre-Amione, H. H. Birdsall, T. S. Ma, and D. L. Mann, “Tumor necrosis factor-α gene and protein expression in adult feline myocardium after endotoxin administration,” Journal of Clinical Investigation, vol. 96, no. 2, pp. 1042–1052, 1995. [71] T. Kubota, C. F. McTiernan, C. S. Frye, A. J. Demetris, and A. M. Feldman, “Cardiac-speciﬁc overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice,” Journal of Cardiac Failure, vol. 3, no. 2, pp. 117–124, 1997. [72] M. R. Bristow, “Tumor necrosis factor-α and cardiomyopa- thy,” Circulation, vol. 97, no. 14, pp. 1340–1341, 1998.